Sensei Biotherapeutics : Regulation FD Disclosure - Form 8-K
November 06, 2023 at 04:44 pm IST
Share
Item 7.01
Regulation FD Disclosure.
On November 6, 2023, Sensei Biotherapeutics, Inc. (the "Company") confirmed that on October 25, 2023 it received an unsolicited proposal from Newtyn Management, LLC ("Newtyn") to acquire all of the Company's outstanding shares of common stock at a price of $1.00 per share in cash.
The Company's Board of Directors ("Board") reviewed Newtyn's proposal and determined unanimously that the proposal substantially undervalues the Company and its future prospects and is not in the best interests of the Company and its stockholders. Accordingly, on November 6, 2023, the Board rejected Newtyn's proposal.
The Board believes the Company is well-positioned to continue executing on its strategy and create significant long-term value for stockholders.
The information in Item 7.01 is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, whether filed before or after the date hereof and regardless of any general incorporation language in such filing.
Sensei Biotherapeutics Inc. published this content on 06 November 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 November 2023 11:12:42 UTC.
Sensei Biotherapeutics, Inc. is a clinical-stage immuno-oncology company, which is focused on the discovery and development of therapeutics for cancer patients. Through its Tumor Microenvironment Activated biologics (TMAb) platform, the Company develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Its lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation checkpoint selectively within the low pH tumor microenvironment. It is also developing SNS-102, a conditionally active monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4); SNS-103, a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), CD39; and SNS-201, a conditionally active VISTAxCD28 bispecific antibody.
SENSEI BIOTHERAPEUTICS, INC. 
